These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26156122)

  • 1. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
    Stöhr E; Schmeel FC; Schmeel LC; Hänel M; Schmidt-Wolf IG;
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2205-12. PubMed ID: 26156122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
    Mele G; Melpignano A; Quarta G; Palumbo G; Capalbo S; Falcone A; Cascavilla N; Palazzo G; Mazza P; Iannitto E; Curci P; Rizzi R; Specchia G; Rossini B; Pavone V; Ria R; Vacca A; Buquicchio C; Tarantini G; Minoia C; Guarini A; Ditonno P; Polimeno G; Reddiconto G; Di Renzo N
    Leuk Res; 2015 Mar; 39(3):279-83. PubMed ID: 25636354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
    Yalnız FF; Akkoç N; Salihoğlu A; Ar MC; Öngören Ş; Eşkazan AE; Soysal T; Aydın Y
    Turk J Haematol; 2017 Aug; 34(3):233-238. PubMed ID: 28270368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
    Chamberlain MC; Colman H; Kim BT; Raizer J
    J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine in relapsed/refractory multiple myeloma: the "real-life" side of the moon.
    Musto P; Fraticelli VL; Mansueto G; Madonna E; Nozza A; Andriani A; Mussetti A; Ballanti S; Bongarzoni V; Baraldi A; Patriarca F; Vincelli D; Falcone A; Derudas D; Califano C; Zambello R; Mele G; Fragasso A; Baldini L; Storti S
    Leuk Lymphoma; 2015 May; 56(5):1510-3. PubMed ID: 25651428
    [No Abstract]   [Full Text] [Related]  

  • 10. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine in patients with relapsed or refractory multiple myeloma.
    Michael M; Bruns I; Bölke E; Zohren F; Czibere A; Safaian NN; Neumann F; Haas R; Kobbe G; Fenk R
    Eur J Med Res; 2010 Jan; 15(1):13-9. PubMed ID: 20159666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
    Kropff M; Baylon HG; Hillengass J; Robak T; Hajek R; Liebisch P; Goranov S; Hulin C; Bladé J; Caravita T; Avet-Loiseau H; Moehler TM; Pattou C; Lucy L; Kueenburg E; Glasmacher A; Zerbib R; Facon T
    Haematologica; 2012 May; 97(5):784-91. PubMed ID: 22133776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer.
    Lammers PE; Shyr Y; Li CI; Hutchison AS; Sandler A; Carbone DP; Johnson DH; Keedy VL; Horn L
    J Thorac Oncol; 2014 Apr; 9(4):559-62. PubMed ID: 24736081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
    Palumbo A; Offidani M; Patriarca F; Petrucci MT; Cavo M
    Leuk Lymphoma; 2015 Mar; 56(3):559-67. PubMed ID: 24884319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
    Damaj G; Malard F; Hulin C; Caillot D; Garidi R; Royer B; Marit G; Stoppa AM; Banos A; Morineau N; Moreau P; Fitoussi O; Tiab M; Moreau P
    Leuk Lymphoma; 2012 Apr; 53(4):632-4. PubMed ID: 21916831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
    Goldsmith SR; Fiala MA; Wang B; Schroeder MA; Wildes TM; Ghobadi A; Stockerl-Goldstein K; Vij R
    Ann Hematol; 2020 May; 99(5):1041-1048. PubMed ID: 32130471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
    Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
    Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
    Papanikolaou X; Szymonifka J; Rosenthal A; Heuck CJ; Mitchell A; Johann D; Keller J; Waheed S; Usmani SZ; Van Rhee F; Bailey C; Petty N; Hoering A; Crowley J; Barlogie B
    Haematologica; 2013 Jul; 98(7):1147-53. PubMed ID: 23716540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.